An AbbVie drug being tested for the treatment of fatty liver disease is one of three drugs selected—out of a pool of 130—for a COVID-19 clinical trial launched by the National Institutes of Health.
< BACK TO MAIN NEWS PAGE
An AbbVie drug being tested for the treatment of fatty liver disease is one of three drugs selected—out of a pool of 130—for a COVID-19 clinical trial launched by the National Institutes of Health.